GRI Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-12.77	-13.04	-3.22	-9.3	-4.82	-3.46	Upgrade
Depreciation & Amortization	0.01	0	0	0.07	0.07	0.02	Upgrade
Share-Based Compensation	0.34	0.39	0.03	0.63	0.15	0.08	Upgrade
Other Operating Activities	3.35	3.66	2.1	0.29	0.89	0.48	Upgrade
Operating Cash Flow	-9.08	-8.99	-1.09	-8.31	-3.71	-2.88	Upgrade
Capital Expenditures	-0.01	-0.01	-0	0	-0	0	Upgrade
Change in Investments	0	0	0	-3.84	0	0	Upgrade
Investing Cash Flow	-0.01	-0.01	-0	-3.84	-0	0	Upgrade
Share Issuance / Repurchase	16.74	12.25	-0.12	15.5	0	4.98	Upgrade
Debt Issued / Paid	1.1	1.1	1.24	0.24	-0	1.11	Upgrade
Other Financing Activities	-2.55	-2.55	-0.11	-	-	-	Upgrade
Financing Cash Flow	15.28	10.8	1.01	15.75	-0	6.09	Upgrade
Net Cash Flow	6.2	1.8	-0.08	3.59	-3.71	3.21	Upgrade
Free Cash Flow	-9.09	-9	-1.09	-8.31	-3.71	-2.88	Upgrade
Free Cash Flow Margin	-	-	-	-	-3708.00%	-	Upgrade
Free Cash Flow Per Share	-28.61	-253.43	-109.65	-3469.14	-2246.44	-2217.66	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).